

S W I S S  B R I D G E

INVEST IN CANCER RESEARCH WORLDWIDE

SWISS BRIDGE AWARD

ERFOLGREICHE
FÖRDERUNG DER
INTERNATIONALEN
KREBSFORSCHUNG

*SUCCESSFUL
PROMOTION
OF INTERNATIONAL
CANCER RESEARCH*

20
JAHRE
2000-2020

www.swissbridge.ch

20 JAHRE SWISS BRIDGE AWARD 2000-2020

ALLE GEWINNER SWISS BRIDGE AWARD 2000-2019

Grundsätzlich sollen sich schweizerische und ausländische Forschende die Preissumme teilen

Belgien/Belgium

2010 - Anna Sablina, KU Leuven, 2016 - Jan Cools, VIB Center for The Biology of Disease, Leuven,
2016 - Peter Van Vlierberghe, Ghent University Hospital, Ghent.

Deutschland/Germany

2013 - Heide Götsche, University of Leipzig, 2015 - Andreas Trumpp, Stem Cell and Cancer Center, Heidelberg,
2019 - Lukas Bunse, University Hospital Mannheim.

England/United Kingdom

2001 - Steven C. West, Cancer Research UK, London, 2008 - Thomas Helleday, Radiation Oncology and Biology,
University of Oxford, 2009 - Steven C. West, Cancer Research UK, London.

Frankreich/France

2000 - Edgar Goldgar, International Agency for Research on Cancer, Lyon, 2001 - Silvia Franceschi, International
Agency for Research on Cancer, Lyon, 2006 - Zdenko Herceg, International Agency for Research on Cancer, Lyon,
2014 - Laurence Zitvogel, Gustave Roussy Comprehensive Cancer Centre, Villejuif.

Israel

2010 - Ronit Satchi-Fainaro, Sackler School of Medicine, Tel Aviv, 2011 - Shai Israeli, Sheba Medical Center,
Ramat Gan, 2017 - Yaron Cami, Sackler School of Medicine, Tel Aviv.

Italien/Italy

2001 - Pier Paolo Fiore, European Institut of Oncology, Milano, 2005 - Stefano Piccolo, University of Padua,
2007 - Giuseppe Pelicci, Istituto Europeo di Oncologica, Milano, 2007 - Matteo Cesari, Catholic Universiy of
Sacred Heart, Roma, 2008 - Anna Maria Teti, University of L'Aquila, 2013 - Lisa Licitra, Istituto Nationale dei
Tumori, Milano.

Norwegen/Norway

2004 - Anne-Lise Borresen-Dale, Institute for Cancer Research, Oslo.

Schweden/Sweden

2004 - Rune Toftgard, Karolinska Institute, Stockholm.

Schweiz/Switzerland

2002 - Giulio Spagnoli, University of Basle, 2002 - Francesco Bertoni, Oncology Institute of Southern Switzerland,
Bellinzona, 2002 - Markus G. Manz, Institute for Research in Biomedicine, Bellinzona, 2003 - Gerhard Christofori,
University of Basle, 2003 - Josef Jiricny, Institute of Molecular Cancer Research, University of Zurich, 2004 - Brian
Hemmings, Friedrich Miescher Institute, Basle, 2006 - Matthias Egger, University of Berne, 2007 - Ariel Ruiz,
University of Geneva, 2008 - Dario Neri, ETH Zurich, 2009 - Matthias Egger, Univesity of Berne, 2009 - Wilhelm
Krek, ETH Zurich, 2010 - Andrea Alimonti, Oncology Institute of Southern Switzerland, Bellinzona, 2011 - Jürg
Schwaller, University Hospital, Basle, 2011 - Monika Hegi, University Hospital, Lausanne, 2013 - Christine
Bouchardy, University of Geneva, 2013 - Sibyl Tschudin, University Hospital Basle, 2014 - Adrian Ochsenbein,
University of Berne, 2015 - Joerg Huelsken, EPFL Lausanne, 2016 - Christian Mosimann, University of Zurich,
2016 - Sara Meyer, University Hospital Basle, 2017 - Johanna Joyce, Ludwig Institute for Cancer Research,
Lausanne, 2018 - Ping-Chih Ho, Ludwig Cancer Research, Lausanne,
2019 - Denis Migliorini, Geneva University Hospital, Geneva.

Spanien/Spain

2000 - Maria Blasco, Spanish National Cancer Centre, Madrid, 2005 - Oscar Fernandez-Capellano, Spanish
National Cancer Centre, Madrid, 2006 - Manuel Esteller, Spanish National Cancer Centre, Madrid,
2018 - Rodrigo de Almeida Toledo, d'Hebron Institute of Oncology, Barcelona.

ALL WINNERS SWISS BRIDGE AWARD 2000-2019

**In principle, Swiss and foreign researchers
shall share the prize monies equally**

CHF 500'000 FÜR DIE BESTEN EUROPÄISCHEN KREBS- FORSCHUNGSPROJEKTE

Die Geschichte des SWISS BRIDGE AWARD

SWISS BRIDGE wurde 1997 gegründet mit dem Ziel, eine Brücke zwischen der internationalen Finanzbranche in der Schweiz und der internationalen Krebsforschung zu schlagen. Als Initiant der Stiftung war ich von Anfang an überzeugt, dass Wettbewerb der beste Weg ist, herausragende Resultate zu erzielen. Der erste SWISS BRIDGE AWARD wurde im Jahr 2000 ausgeschrieben. Seither haben ca. 1'200 Forscher ihre Projektideen der internationalen Jury unterbreitet, wovon ca. 150 in die engere Auswahl gelangten, aus denen schliesslich 50 Preisträger erkoren wurden.

Mit der Regelmässigkeit der zur Verfügungstellung der jährlichen Preissumme von mindestens CHF 500'000 avancierte der SWISS BRIDGE AWARD bald zu einem der begehrtesten Preise in der europäischen Krebsforschung. Diese Leistung hat die Schweizerische Krebsliga 2017 mit dem Anerkennungspreis gewürdigt.



Würdigung des Präsidenten des Stiftungsrats

Es ist sehr bemerkenswert, wie erfolgreich die Stiftung SWISS BRIDGE und natürlich dieser wunderbare Award sich in den letzten 20 Jahren entwickelt hat. Als ehemaliger Präsident der Krebsliga Schweiz freue ich mich umso mehr, dass der Initiant der SWISS BRIDGE Foundation 2017 für seine wertvolle Arbeit mit dem Anerkennungspreis der Krebsliga ausgezeichnet wurde.

Jakob Passweg



Appraisal by the Chairman of the Scientific Jury

Swiss Bridge has met an important need by funding promising projects still in embryo, and very often helped young cancer scientists and doctors get on to the first rung in their careers. We profile some of the many success stories here, emerging from your contributions to SWISS BRIDGE, but there are many more untold. SWISS BRIDGE was one of the first charities to see the potential of immuno-oncology a decade ahead of the larger European funders. I commend the three leaders highlighted below, Prof Dr Markus Manz, Prof Dr Matthias Egger and Prof Dr Laurence Zitvogel, and ask SWISS BRIDGE to continue to support the next generation of brilliant scientists.

Ronald Heuvelie



Wertschätzung des CEO der Stiftung

Selbstverständlich bin ich äusserst stolz darauf, diese wichtige Funktion des CEOs bei der Stiftung SWISS BRIDGE bekleiden zu dürfen. Es ist eine grosse Ehre für mich, dass mir dieses Erbe übergeben wurde. Somit werde ich mein ganzes Engagement daransetzen, die Stiftung in den nächsten Jahren erfolgreich im Kampf gegen den Krebs weiterzuentwickeln.

Mr. Lüscher

20
JAHRE
2000-2020



Prof. Dr. Markus G. Manz

**Director of Medical Oncology and Haematology
at the University of Zurich, Zurich
and Professor at the University of Zurich**

SWISS BRIDGE AWARD 2002

Das Projekt dieses jungen Forschers "**modelling cellular immunotherapy in cancer**", damals Forschungsgruppenleiter am Institut für Biomedizinische Forschung, Bellinzona, hat die Aufmerksamkeit der Jury auf sich gezogen. Immunotherapie bei Krebs ist heute das hochaktuelle Thema wegen dem hohen klinischen Nutzen für Patienten mit vielen unterschiedlichen Formen von Krebs.

Professor Manz ist heute Klinikdirektor der Klinik für Medizinische Onkologie und Hämatologie am UniversitätsSpital Zürich und lehrt an der Universität Zürich und der Eidgenössischen Technischen Hochschule Zürich. Er leitet zudem seine eigene Forschungsgruppe mit Schwerpunkt Blutstammzellen und Blutkrebs.

For basic cancer research, genetics and epidemiology

The project of this young investigator "**modelling cellular immunotherapy in cancer**", at the time research group-leader at the Institute for Research in Biomedicine, Bellinzona, has attracted the attention of the Jury. Immunotherapy in cancer has today become the hot topic due to excellent clinical benefits in patients with many different forms of cancer.

Professor Manz is today Director of the department of medical oncology and hematology at the University Hospital Zurich and teaches at the University of Zurich and the Federal Institute of Technology Zurich. Also, he is leading his own research group in the field of blood-stem-cells and blood-cancer.

Chairman's appraisal

Professor Manz was a young group-leader, recently arrived in Bellinzona from Stanford University, when he submitted his project to SWISS BRIDGE, eighteen years ago. It was based around the study of dendritic cells, the Cinderellas of the immune system. He wanted to know where these cells came from, their link to blood-stem-cells, their contribution to immune surveillance and potential role in cancer.

His SWISS BRIDGE AWARD was to be the first of many accolades, and was certainly the first important step, not only in his independent career but also in the dissection of the role of dendritic and stem cells in cancer immunology. Since then immune-oncology has mushroomed to be the main new weapon in the fight against cancer. Clinical trials of antibodies, cell cycle targeted molecules and chimeric antigen receptor (CAR) T-cell therapies have shown astonishing responses in patients with all kinds of cancers. Now Professor Manz is an international leader in hematologic cancers such as leukaemia and lymphoma.



Prof. Dr. med. Matthias Egger

**Head of Research Group
Research – HIV and Tuberculosis
at the Institute of Social and Preventive Medicine,
University of Berne, Switzerland**

SWISS BRIDGE AWARD 2009

38 nominierte Kandidaten für den SWISS BRIDGE AWARD 2000-2008 waren eingeladen, ein neues Projekt einzureichen. Das Projekt von Prof. Egger vom Institut für Sozial- und Präventionsmedizin an der Universität Bern "**AIDS defining Cancers in Southern Africa in the era of ART**" wurde nebst zwei weiteren Projekten zur Finanzierung ausgewählt.

Professor Egger leitet an der Universität Bern eine Forschungsgruppe zu HIV und Tuberkulose, die hauptsächlich von den US National Institutes of Health (NIH) und vom Schweizerischen Nationalfonds finanziert wird.

Sein Arbeitsgebiet konzentriert sich im Wesentlichen auf methodische und inhaltliche Fragen der klinischen Epidemiologie und Public Health, wobei der Schwerpunkt auf longitudinalen Kohortenstudien und meta-analytischer Forschung zu HIV/AIDS und anderen Infektionskrankheiten und Krebs in Afrika liegt.

For all award nominees from 2000-2008

38 nominees of the SWISS BRIDGE AWARD 2000-2008 were invited to submit a new project. The project of Prof Egger from the Institute for Social- and Prevention-medicine of the University of Berne "**AIDS defining Cancers in Southern Africa in the era of ART**" was chosen to be awarded alongside two other projects.

Professor Egger heads a research group on HIV and Tuberculosis at the University of Bern, which is mainly funded by the US National Institutes of Health (NIH), and by the Swiss Nationalfonds.

His field of work focuses on methodological and substantive issues in clinical epidemiology and public health medicine, with a focus on longitudinal cohort studies and meta-analytical research in HIV/AIDS and other infectious diseases as well as cancer in sub-Saharan Africa.

Chairman's appraisal

In Southern Africa, where HIV infection is common, AIDS-defining cancers are an important public health issue. With the scale-up of combination antiretroviral therapy (ART) in Africa the prognosis of individuals living with HIV/AIDS has been improved substantially, with mortality rates approaching those of the general population. The implications for the burden of cancer in the HIV-infected population, and for treatment and outcome of AIDS-defining cancers like Kaposi sarcoma, non-Hodgkin's lymphoma and cervical cancer are unclear at present.

Professor Matthias Egger of the Institute of Social and Preventive Medicine at the University of Berne aims to bridge these gaps. In his research projects in the area of epidemiology, health services and clinic, the prevention and treatment of AIDS-defining cancers in the region are being studied. The aim is to evaluate the incidence, the clinical stages at diagnosis and the prognosis, to examine the provision of health care to these patients and build relevant capacity. The International Epidemiological Databases to evaluate AIDS in Southern Africa (leDEA-SA), a large network of HIV programmes including data on ART patients in Botswana, Malawi, Mozambique, South Africa, Zambia and Zimbabwe, will serve as the research platform.

20 JAHRE SWISS BRIDGE AWARD 2000-2020



Prof Dr. Laurence Zitvogel

**Professor of immunobiology
at the University of Paris-Saclay
Medical School, and science director
at the Immuno-Oncology Program
at the Gustave Roussy Cancer Centre,
Villejuif, France**

SWISS BRIDGE AWARD 2014

Prof. Zitvogel vom Gustave Roussy Comprehensive Cancer Centre, Villejuif, Frankreich, wurde ausgezeichnet für ihr Projekt **“Impact of gut microbiota in the efficacy and toxicity of immune checkpoints blockers in oncology”**.

Sie wurde ausgewählt für ihre Entdeckungen im Bereich der Immuno-Onkologie, als Grundlage für wichtige Fortschritte und das fundamentale Verständnis von Krebs-Immunologie.

For immunotherapy in oncology

Prof. Zitvogel from the Gustave Roussy Comprehensive Cancer Centre, Villejuif, France was chosen for her project **“Impact of gut microbiota in the efficacy and toxicity of immune checkpoints blocker in oncology”**.

She was distinguished for her discoveries in the area of immuno-oncology. They serve as the foundation for important advances and our understanding of the fundamentals of cancer immunology.

Chairman's appraisal

Professor Zitvogel was one of the first immunobiologist to launch the new immuno-oncology antibodies in cancer, and she showed surprising beneficial effects. But always, a pioneer, driven by curiosity on the mechanism of these antibodies plus the reasons for failure, she went on to examine the microbes in the large bowel of her patients to detect links to the clinical effect. Five years on she has become the doyenne of the microbiome, not only in Europe but globally too. She is without doubt an original thinker, a questioning laboratory scientist and a compassionate doctor. We at SWISS BRIDGE share pride in her achievements, which have led to many accolades including the first ESMO (European Society for Medical Oncology) Award for Immuno-Oncology presented on Dec. 7 during the ESMO Immuno-Oncology Congress 2017 [2] in Geneva, Switzerland, along with a keynote lecture, “Introducing the gut microbiome into the complexity of anticancer immuno-surveillance.”

Laurence Zitvogel

I was very honored of this distinction from the SWISS BRIDGE 5 years ago and could discover the role of enterophagie in tumor immuno-surveillance. We identified a phage bearing an aminoacid sequence sharing molecular mimicry with cancer antigens, allowing the elicitation of effector T lymphocytes that patrol and recirculate from the gut lymphoid system to tumor beds, contributing to tumor rejection during various immunomodulators. This award was very unique to encourage the first author in conducting this complex discovery and we feel very indebted to SWISS BRIDGE since then. We wish to support other generations of young scientists to decipher the mysteries of nature!

UNSEREN SPENDERN EINE STIMME GEBEN

Drei Formen von Spenden

Designierte Spenden

Donatoren können, unter Vorbehalt der Zustimmung der wissenschaftlichen Jury, die Verwendung ihrer Spende für ein ausgewähltes Forschungsprojekt und/oder ein bevorzugtes Forschungs-Institut irgendwo auf der Welt bestimmen. Solche Beiträge werden ohne Abzug von Spesen an das designierte und bewilligte Institut überwiesen.

Nicht designierte Spenden

Donatoren können die Verwendung ihrer Spende der wissenschaftlichen Jury der Stiftung anvertrauen. Solche Spenden werden hauptsächlich für die Finanzierung des jährlichen SWISS BRIDGE AWARD, oder für bewilligte aber nicht voll finanzierte Forschungsprojekte verwendet.

Supporter und Freunde der Stiftung

Diese Donatoren unterstützen die Stiftung mit Spenden zur freien Verfügung. Solche Beiträge fließen in den internen Fonds "Supporter und Freunde der Stiftung". Der Stiftungsrat beschliesst jährlich die Verwendung dieser Mittel für bereits bewilligte, noch nicht voll finanzierte Forschungsprojekte oder für die Verwaltung der Stiftung.

Steuer-Status

SWISS BRIDGE ist eine wegen Gemeinnützigkeit steuerbefreite schweizerische Stiftung. Spenden können demzufolge gemäss dem Steuerrecht des Bundes und der Kantone soweit rechtlich zulässig, in der Steuerklärung in Abzug gebracht werden.

**Wenn Sie jemanden kennen,
der Spender oder Supporter
und Freund der Stiftung SWISS BRIDGE
werden möchte, bitten wir Sie,
uns zu kontaktieren.**

A VOICE TO OUR DONORS

Three kinds of donations

Designated Donations

Donors may wish, that the utilisation of their donations are for specific cancer research projects and/or for a preferred cancer research institute anywhere in the world, subject to the approval of the Scientific Jury. Such contributions will be transferred to the designated and approved Institutes without deduction of expenses.

Non-designated Donations

Donors may entrust the utilisation of their contributions to the Scientific Jury of the Foundation. Such donations will be primarily used for the financing of the annual SWISS BRIDGE AWARD, or for cancer research projects approved but not fully financed.

Supporter and Friends of the Foundation

These donors support the Foundation with contributions for discretionary use. Such donations are assigned to the internal funds "Supporters and Friends of the Foundation". The Board of Foundation decides annually the utilisation of these funds, partly for approved but not fully financed research projects or for the administration of the Foundation.

Tax Status

SWISS BRIDGE is a tax-exempt charitable foundation based in Switzerland. Donations may therefore be deducted from taxes in Switzerland to the legally permissible extent in accordance with the tax laws of the Swiss federal and cantonal governments.

**If you know anyone,
who may want to become a donor
or a supporter and friend
of the foundation SWISS BRIDGE,
please contact us.**

**HERZLICHEN DANK
AN DIE SPONSOREN
FÜR DEN JUBILÄUMSANLASS**

**MANY THANKS
TO THE SPONSORS
OF THE ANNIVERSARY EVENT**

RB Rahn+Bodmer
BANQUIERS SEIT 1750

medinfo
AERZTEVERLAG

krebsforschung schweiz

SWISS BRIDGE
INVEST IN CANCER RESEARCH WORLDWIDE

**Basic and translational research
in childhood cancer**

SWISS BRIDGE AWARD 2020

Board of Foundation

Prof. Dr. Jakob Passweg (Chairman)
Liv Bahner, Zürich
Eleonore E. Droux, Herrliberg
Yves Monnard, Zürich
Dr. Thomas Peter, Küschnacht

Founder of Foundation

Thomas Hoepli, Lenzerheide

Honorary Chairman

Prof. Dr. Giorgio Noseda

Scientific Jury

Prof. Dr. Gordon McVie (Chairman)

Management

Philipp Lücke (CEO)

Board of Patrons

Dr. med. Jacques Bernier, Geneva
Prof. Dr. Paul Kleihues, Zürich
Prof. Dr. med. Dr. h.c. Urs Metzger, Zürich
Sir Paul Nurse, London
Heinz Roth, Uitikon/Waldegg
Prof. Dr. med. Thomas Szucs, Zollikon

Administration

SWISS BRIDGE
Postfach 1556 · 8027 Zürich
Tel. +41 (0) 43 3171360
info@swissbridge.ch · www.swissbridge.ch

Donors account:

Credit Suisse, Zurich, IBAN: CH52 0483 5095 7385 1100

www.swissbridge.ch

20
JAHRE
2000-2020